ALRN (Aileron Therapeutics, Inc.) רווח למניה בארבעת הרבעונים האחרונים

Aileron Therapeutics' authority in developing targeted oncology therapies defines a trend where the relative YoY EPS growth over the last 12 months demonstrates a fresh parameter 40.40. US chemotherapy cell protection centers provide stability. The orphan status of the drugs guarantees the resilience of its positions, keeping patients within a specialized niche ecosystem.
Aileron - פילוחים אנליטיים ומדדי מפתח (ALRN)

This indicator measures the dynamics of net income per share over a rolling year, reflecting the actual pace of capitalization expansion. The metric allows an investor to assess cost management efficiency and the speed of business scaling. By analyzing the annual percentage growth of EPS TTM, one can identify asset overbought conditions or confirm a sustainable trend. For Aileron Therapeutics (ALRN), this indicator is critical during the development of radiation protective drugs. The success of innovative chemical protection converts directly into profit growth, confirming the commercial viability of the technology.